| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. | 78% | -1.5% | $79,920,034 | 66,049,615 | 0% | Citius Pharmaceuticals, Inc. | 10 Dec 2025 | |
| ARMISTICE CAPITAL, LLC | 10% | +2% | $8,886,244 | +$442,742 | 8,078,404 | +5.2% | Armistice Capital, LLC | 31 Dec 2025 |
As of 31 Dec 2025, 17 institutional investors reported holding 6,861,177 shares of CITIUS ONCOLOGY, INC. - Common stock, $0.0001 par value (CTOR). This represents 8.5% of the company’s total 80,864,905 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 6,861,177 | $6,861,177 | -$1,583,956 | $1.00 | 17 |
| 2025 Q3 | 8,357,159 | $16,966,429 | +$16,255,712 | $2.03 | 16 |
| 2025 Q2 | 227,492 | $989,589 | +$573,842 | $4.35 | 7 |
| 2025 Q1 | 105,008 | $97,657 | -$115,519 | $0.93 | 6 |
| 2024 Q4 | 200,884 | $230,191 | +$180,602 | $1.15 | 11 |
| 2024 Q3 | 41,238 | $57,016 | +$57,016 | $1.39 | 7 |